Poster Session 82

Mechanisms relevant to therapy resistance in urothelial tumours

**Poster Session 82**

**Location:** Room Vienna (Hall B2, level 0)

**Chairs:**
R. Nawroth, Munich (DE)
E. Oosterwijk, Nijmegen (NL)

**Aims and objectives of this presentation**
Therapy resistance in prostate cancer develops as a result of activation of multiple signaling pathways. Understanding these mechanisms is a condition for a more efficient therapy. Several abstracts in this session will focus on experimental approaches to combat resistance.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

---

1042
**Association between PDL1 variants and muscle invasive bladder cancer prognosis**


*Institutes:* 1 Hôpitaux Universitaires Henri Mondor, Dept. of Urology, Créteil, France, 2 CNIO, Dept. of Genetic and Molecular Epidemiology, Madrid, Spain, 3 Ramon Y Cajal Hospital, Dept. of Oncology, Madrid, Spain, 4 Oviedo University, Dept. of Preventive Medicine, Oviedo, Spain, 5 NCI, Dept. of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services, Bethesda, Maryland, United States of America, 6 Hôpitaux Universitaires Henri Mondor, Dept. of Pathology, Créteil, France, 7 CNIO, Dept. of Epithelial Carcinogenesis, Madrid, Spain

1043
**Pretreatment neutrophil-to-lymphocyte ratio predicts worse survival outcomes and advanced tumour staging in patients undergoing radical cystectomy for bladder cancer**

*By:* Tan Y. G., Eu E., Huang H. H., Lau W. K. O.

*Institutes:* Singapore General Hospital, Dept. of Urology, Singapore, Singapore

1044
**Neutrophil-to-lymphocyte ratio as a prognostic factor for survival in patients with bladder cancer undergoing radical cystectomy**

*By:* Jiménez Marrero P. 1, Pérez Sanchez M. 1, Jorge Pérez N. 1, González J. M. 2, Kim Lee D. 1, Marrero Umpierrez N. 1, Hernández Hernández C. 1, Hernández Escobar S. 1, Marrero Dominguez R. 1

*Institutes:* 1 University Hospital of Gran Canaria Dr. Negrín, Dept. of Urology, Las Palmas de Gran Canaria, Spain, 2 University Hospital of Gran Canaria Dr. Negrín, Dept. of Research, Las Palmas de Gran Canaria, Spain

1045
**EpCAM (epithelial cell adhesion molecule) as the most common target for circulating tumor cells (CTC) identification: Comparison between manual and automated system of isolation and future prospective**

*By:* Busetto G. M. 1, Giovannone R. 1, Antonini G. 1, Gazzaniga P. 2, Gentile V. 1, De Berardinis E. 1

*Institutes:* 1 Sapienza Rome University Policlinico Umberto I, Dept. of Urology, Rome, Italy, 2 Sapienza Rome University Policlinico Umberto I, Dept. of Molecular Medicine, Rome, Italy

1046
**Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma**

*By:* Todenhöfer T. 1, Kamyabi A. 1, Hennenlotter J. 2, Seiler R. 1, Mcdonald P. 3, Moskalev I. 1, Stewart C. 1, Gao J. 1, Bedke J. 2, Oo H. Z. 1, Fazli L. 1, Dedhar S. 3, Stenzl A. 2, Black P. 1

*Institutes:* 1 University of British Columbia, Vancouver Prostate Centre, Vancouver, Canada, 2 Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany, 3 British Columbia Cancer Research Centre, Dept. of Integrative Oncology, Vancouver, Canada
1047  En bloc bipolar resection to optimize TURB samples for organotypic culture and development of targeted treatments in non-muscle invasive bladder cancer  
By: Daniel G.¹, Roumiguié M.², Fons P.³, Herbert C.⁴, Brousset P.¹, Mazerolles C.¹, Malavaud B.²  
Institutes: ¹Institut Universitaire Du Cancer, Dept. of Pathology, Toulouse, France, ²Institut Universitaire Du Cancer, Dept. of Urology, Toulouse, France, ³EVOTEC France, Clinical Translation Group, Toulouse, France, ⁴EVOTEC France, Dept. of Biology, Toulouse, France

1048  Assessment of the efficacy of repeated instillations of TC-gel mixed with MMC in an invasive rat bladder cancer model  
By: Van Valenberg F.J.P.¹, Strauss-Ayali D.², Agmon-Gerstein Y.², Friedman A.², Areten H.C.¹, Witjes J.A.¹, Oosterwijk E.¹  
Institutes: Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, ²UroGen Pharma Ltd., Intravesical Drug Delivery Solutions, Ra’anana, Israel

1049  Benzyl isothiocyanate up-regulates miR-99a-5p and induces autophagy by suppressing mTOR expression  
By: Tsai T-F.¹, Lin J-F.², Lin Y-C.¹, Chen H-E.¹, Chou K-Y.¹, Hwang T.I.S.¹  
Institutes: ¹Shin Kong Wu Ho-Su Mem. Hospital, Dept. of Urology, Taipei, Taiwan, ²Shin Kong Wu Ho-Su Mem. Hospital, Central Laboratory, Taipei, Taiwan

1050  Foxp3 interacts with and regulates HIF-1α-VEGF signaling in human bladder cancer  
By: Tsai Y-S.¹, Kao Y-L.², Wu K-Y.¹, Jou Y-C.², Chen S-Y.², Tsai H-T.², Tzai T-S.³  
Institutes: ¹National Cheng Kung University Hospital, Dept. of Urology, Tainan, Taiwan, ²Christian Chia-Yi Hospital, Dept. of Urology, Chia-Yi, Taiwan, ³National Cheng Kung Hospital, Dept. of Urology, Tainan, Taiwan

1051  Multiple drug induced feedback loops limit the efficacy of PI3K/AKT/mTOR inhibition as a therapy in bladder cancer  
Institutes: Klinikum Rechts der Isar der Technischen Universität Muenchen, Dept. of Urology, Munich, Germany

1052  Inhibition of cisplatin-induced autophagy enhances apoptotic cell death in human bladder cancer  
By: Hwang T.¹, Lin J-F.², Lin Y-C.¹, Tsai T-F.¹, Chen H-E.¹, Chou K-Y.¹  
Institutes: ¹Shin Kong Wu Ho-Su Mem. Hospital, Dept. of Urology, Taipei, Taiwan, ²Shin Kong Wu Ho-Su Mem. Hospital, Central Laboratory, Taipei, Taiwan

1053  Endoplasmic reticulum stress as a putative mechanism for attenuated response to intravesical BCG in bladder cancer  
By: Lewicki P.¹, Liu H.¹, O’ Malley P.¹, Golombos D.¹, Cubillos-Ruiz J.², Scherr D.¹  
Institutes: ¹Weill Cornell Medical College, Dept. of Urology, New York, United States of America, ²Weill Cornell Medical College, Dept. of Obstetrics and Gynecology, New York, United States of America